ATARA Biotherapeutics (ATRA) Misses Q1 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts ATRA Hot Sheet
Join SI Premium – FREE
ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.29). Revenue for the quarter came in at $520 thousand.
For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rosenblatt keeps Buy rating on Marvell after Lumentum acquisition
- Trump: Iran wants a settlement, as soon as possible. It could happen
- Check Point Software Technology (CHKP) call put ratio 1.2 calls to 1 put with a focus on November puts as share price down 6.2%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
